These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 8529328)

  • 1. Tolrestat pharmacokinetic and pharmacodynamic effects on red blood cell sorbitol levels in normal volunteers and in patients with insulin-dependent diabetes.
    van Griensven JM; Jusko WJ; Lemkes HH; Kroon R; Verhorst CJ; Chiang ST; Cohen AF
    Clin Pharmacol Ther; 1995 Dec; 58(6):631-40. PubMed ID: 8529328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of the aldose reductase inhibitor tolrestat: studies in healthy young and elderly male and female subjects and in subjects with diabetes.
    Fruncillo R; Troy S; Parker V; Mayersohn M; Hicks D; Kraml M; Battle M; Chiang S
    Clin Pharmacol Ther; 1996 Jun; 59(6):603-12. PubMed ID: 8681485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of tolrestat on red blood cell sorbitol levels in patients with diabetes.
    Raskin P; Rosenstock J; Challis P; Ryder S; Mullane JF; Gonzalez R; Hicks D; Smith T; Dvornik D
    Clin Pharmacol Ther; 1985 Dec; 38(6):625-30. PubMed ID: 4064465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
    Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correction of nerve conduction and endoneurial blood flow deficits by the aldose reductase inhibitor, tolrestat, in diabetic rats.
    Cotter MA; Cameron NE; Hohman TC
    J Peripher Nerv Syst; 1998; 3(3):217-23. PubMed ID: 10959252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Duration of action and pharmacokinetics of the oral antidiabetic drug gliquidone in patients with non-insulin-dependent (type 2) diabetes mellitus.
    von Nicolai H; Brickl R; Eschey H; Greischel A; Heinzel G; König E; Limmer J; Rupprecht E
    Arzneimittelforschung; 1997 Mar; 47(3):247-52. PubMed ID: 9105542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Red cell sorbitol and diabetic control.
    Akgün S; Ertel NH; Kemp FW
    Horm Metab Res; 1985 Jul; 17(7):355-7. PubMed ID: 4029876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erythrocytic sorbitol contents in diabetic patients correlate with blood aldose reductase protein contents and plasma glucose levels, and are normalized by the potent aldose reductase inhibitor fidarestat (SNK-860).
    Asano T; Saito Y; Kawakami M; Yamada N; Sekino H; Hasegawa S;
    J Diabetes Complications; 2004; 18(6):336-42. PubMed ID: 15531183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of multiple dosing and age on the pharmacokinetics and pharmacodynamics of glipizide in patients with type II diabetes mellitus.
    Jaber LA; Ducharme MP; Edwards DJ; Slaughter RL; Grunberger G
    Pharmacotherapy; 1996; 16(5):760-8. PubMed ID: 8888072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.
    O'Farrell AM; van Vliet A; Abou Farha K; Cherrington JM; Campbell DA; Li X; Hanway D; Li J; Guler HP
    Clin Ther; 2007 Aug; 29(8):1692-705. PubMed ID: 17919550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
    Smith WB; Dowell JA; Pratt RD
    Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study.
    Zhao RK; Cheng G; Tang J; Song J; Peng WX
    Clin Ther; 2009 May; 31(5):1022-36. PubMed ID: 19539103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacokinetics and pharmacodynamics of a new squalene synthase inhibitor, BMS-188494, in healthy volunteers.
    Sharma A; Slugg PH; Hammett JL; Jusko WJ
    J Clin Pharmacol; 1998 Dec; 38(12):1116-21. PubMed ID: 11301563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses.
    Herman GA; Stevens C; Van Dyck K; Bergman A; Yi B; De Smet M; Snyder K; Hilliard D; Tanen M; Tanaka W; Wang AQ; Zeng W; Musson D; Winchell G; Davies MJ; Ramael S; Gottesdiener KM; Wagner JA
    Clin Pharmacol Ther; 2005 Dec; 78(6):675-88. PubMed ID: 16338283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Reduction of erythrocyte sorbitol by ascorbic acid in patients with diabetes mellitus].
    Wang H; Zhang ZB; Wen RR
    Zhonghua Yi Xue Za Zhi; 1994 Sep; 74(9):548-51, 583. PubMed ID: 7842354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects.
    Cilla DD; Whitfield LR; Gibson DM; Sedman AJ; Posvar EL
    Clin Pharmacol Ther; 1996 Dec; 60(6):687-95. PubMed ID: 8988072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of acute glutathione treatment on sorbitol level in erythrocytes from diabetic patients.
    Ciuchi E; Odetti P; Prando R
    Diabetes Metab; 1997 Feb; 23(1):58-60. PubMed ID: 9059767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics, pharmacodynamics, tolerability, and safety of a novel sorbitol dehydrogenase inhibitor in healthy participants.
    Landau Z; Novotny MJ; Preston GM; Wright K; Freeman T; Dai H; Thompson J; Oates PJ; Calle RA
    J Clin Pharmacol; 2010 May; 50(5):521-30. PubMed ID: 20220044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of pharmacokinetic and pharmacodynamic properties of single-dose oral insulin spray and subcutaneous insulin injection in healthy subjects using the euglycemic clamp technique.
    Cernea S; Kidron M; Wohlgelernter J; Modi P; Raz I
    Clin Ther; 2004 Dec; 26(12):2084-91. PubMed ID: 15823772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of 5-fluorouracil pharmacokinetics in whole blood, plasma, and red blood cells in patients with colorectal cancer.
    Wattanatorn W; McLeod HL; Macklon F; Reid M; Kendle KE; Cassidy J
    Pharmacotherapy; 1997; 17(5):881-6. PubMed ID: 9324177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.